Details: pack, label wording, sources, registration
OTOPET THERAPY, Ear drops
rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Complete authorised canine scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation
6.1/10
Situational / acceptable
Details →
vetman assessment
OTOPET THERAPY
×
rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
Assessed clinical scope Dog · Complete authorised canine scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation · Into the ear
Care setting Veterinary otoscopy/cytology-led treatment with careful cleaning, intact-tympanum confirmation, owner twice-daily application and clinical/cytologic recheck
vetman score
6.1/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, veterinary · № 1-03/44 · Verified on 23 Oct 2026
A situational five-active canine otic option when otoscopy and cytology genuinely support its relevant antibacterial, antifungal, acaricidal and steroid components. It should not be a default for every inflamed ear; no direct modern exact-product outcome programme was found, and tympanic, carbaryl, steroid and stewardship risks require controls.
Regulatory and scientific credibility 8.5/10
Exact rifaximin 10 mg/ml, colistin sulfate 200,000 IU/ml, miconazole 17.4 mg/ml, carbaryl 10 mg/ml and triamcinolone 0.908 mg/ml identity, dog/cat route, regimen and perforation/handler restrictions are transparent in current Georgian and multiple current EU regulator records. Credibility is reduced by legacy development, no public modern exact-product assessment or quantified adverse-event/outcome dossier, and a broad inflammation-only label scope that conflicts with current stewardship.
Clinical efficacy 6.0/10
Antibacterial, antifungal, acaricidal and anti-inflammatory components are mechanistically plausible for mixed canine otitis, and topical combination therapy is established when cytology supports it. No controlled exact-product outcome study was found, each component is not needed in every ear, and inflammation-only, resistant-rod, primary allergic or middle-ear disease is not solved by blanket five-active exposure.
Safety and tolerability 4.5/10
The label reports no adverse reactions and permits reproduction, but modern quantified exact safety evidence is absent. Perforation is contraindicated; colistin/polymyxin-class ototoxicity concern, carbaryl cholinesterase inhibition/dermal absorption, topical steroid effects, contact irritation and dual-antibiotic selection pressure require active controls.
Clinical practicality 5.0/10
A fixed 1-2 ml per ear avoids weight calculation and massage aids distribution. Twice-daily shaking, careful cleaning, relatively large oily volume for 7-10 days, restraint/handling, gloves, tympanum examination, cytology and recheck are substantial burdens; canal size makes the twofold volume range a clinician decision rather than a simple owner rule.
Full-course cost-effectiveness -
Current Georgian course price was unavailable; price is excluded from the denominator.
Important safety and use flags
Scope boundary: this canine score covers the full labelled external-otitis scope. It does not cover otitis media/interna, every inflamed ear, undiagnosed neurologic signs or use in another species. Examine before treating: perform otoscopy, confirm an intact tympanic membrane and obtain cytology in every case (stained dry mount plus mite wet mount as appropriate). Culture/susceptibility is important with rods, chronic/recurrent disease, prior antimicrobial exposure or poor response. Cause-directed care: identify allergy, foreign body, conformation, keratinisation/endocrine disease, polyp/mass, parasites or middle-ear disease. Antimicrobials treat secondary overgrowth/infection but do not correct the primary driver of recurrence. Exact administration: shake well, clean carefully, instil 1-2 ml into each affected external canal and massage twice daily for 7-10 days. This is a clinician-selected fixed per-ear range, not a body-weight calculator; do not place it in an unexamined/perforated ear. Stewardship: do not expose a cytology-negative merely inflamed ear to rifaximin, colistin and miconazole by default. At recheck, narrow/stop/switch according to clinical and cytologic response; persistent rods require culture and a documented plan rather than repeated empirical courses. Parasitic boundary: repeat the course after 10 days only for confirmed/suspected parasitic otitis under the label plan. Confirm Otodectes, examine/treat relevant in-contact animals and manage the environment; this repeat instruction is not for every bacterial or yeast episode. Tympanic/neurologic safety: stop and urgently reassess hearing loss, head tilt, nystagmus, ataxia, facial/Horner signs, severe pain or neurologic deterioration. Perforation is contraindicated and suspected middle-ear disease needs sampling/imaging/appropriate non-ototoxic care. Carbaryl safety: wear impermeable gloves and avoid skin/eye contact. Review organophosphates and other cholinesterase inhibitors; hypersalivation, vomiting/diarrhoea, miosis, fasciculation, weakness, dyspnoea or seizure may indicate systemic cholinergic toxicity. Dog safety/recheck: stop for marked irritation, worsening erythema/exudate, systemic steroid effects or hypersensitivity. Recheck clinical signs and cytology; visible improvement alone does not prove microbial resolution or control of allergic disease. Reproduction and handling boundary: the exact label permits pregnancy and lactation at the recommended regimen, but modern quantified exact-product safety data are limited. Prevent licking/eye exposure, wash hands after use, keep the bottle from children and dispose as veterinary waste. Assessment sources +
Close
Cat
Complete authorised feline scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation
5.7/10
Weak evidence support
Details →
vetman assessment
OTOPET THERAPY
×
rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
Assessed clinical scope Cat · Complete authorised feline scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation · Into the ear
Care setting Veterinary otoscopy/cytology-led treatment with careful cleaning, intact-tympanum confirmation, owner twice-daily application and clinical/cytologic recheck
vetman score
5.7/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, veterinary · № 1-03/44 · Verified on 23 Oct 2026
A weak, highly selective feline otic option when mites and/or matching secondary microbes are documented and the tympanic membrane is intact. The absence of direct feline exact-product outcomes, broad inflammation-only label, contact-reaction concern and complex five-active safety/stewardship burden keep the score low.
Regulatory and scientific credibility 8.5/10
Exact rifaximin 10 mg/ml, colistin sulfate 200,000 IU/ml, miconazole 17.4 mg/ml, carbaryl 10 mg/ml and triamcinolone 0.908 mg/ml identity, dog/cat route, regimen and perforation/handler restrictions are transparent in current Georgian and multiple current EU regulator records. Credibility is reduced by legacy development, no public modern exact-product assessment or quantified adverse-event/outcome dossier, and a broad inflammation-only label scope that conflicts with current stewardship.
Clinical efficacy 5.0/10
The component roles are plausible, especially for confirmed Otodectes with secondary microbial inflammation, but no controlled exact-product feline outcome study was found. Feline otitis more often requires targeted investigation for mites, polyps, masses or middle-ear disease, and a broad five-active mixture for cytology-negative inflammation has a particularly weak evidence basis.
Safety and tolerability 4.0/10
The label reports no adverse reactions and permits reproduction, but modern quantified feline safety evidence is absent. Cats may be particularly prone to otic contact reactions; perforation/ototoxicity, carbaryl systemic cholinergic exposure, topical steroid effects and unnecessary dual-antibiotic exposure make the safety ceiling lower than in dogs.
Clinical practicality 5.0/10
A fixed 1-2 ml per ear avoids weight calculation and massage aids distribution. Twice-daily shaking, careful cleaning, relatively large oily volume for 7-10 days, restraint/handling, gloves, tympanum examination, cytology and recheck are substantial burdens; canal size makes the twofold volume range a clinician decision rather than a simple owner rule.
Full-course cost-effectiveness -
Current Georgian course price was unavailable; price is excluded from the denominator.
Important safety and use flags
Scope boundary: this feline score covers the full labelled external-otitis scope. It does not cover otitis media/interna, every inflamed ear, undiagnosed neurologic signs or use in another species. Examine before treating: perform otoscopy, confirm an intact tympanic membrane and obtain cytology in every case (stained dry mount plus mite wet mount as appropriate). Culture/susceptibility is important with rods, chronic/recurrent disease, prior antimicrobial exposure or poor response. Cause-directed care: identify allergy, foreign body, conformation, keratinisation/endocrine disease, polyp/mass, parasites or middle-ear disease. Antimicrobials treat secondary overgrowth/infection but do not correct the primary driver of recurrence. Exact administration: shake well, clean carefully, instil 1-2 ml into each affected external canal and massage twice daily for 7-10 days. This is a clinician-selected fixed per-ear range, not a body-weight calculator; do not place it in an unexamined/perforated ear. Stewardship: do not expose a cytology-negative merely inflamed ear to rifaximin, colistin and miconazole by default. At recheck, narrow/stop/switch according to clinical and cytologic response; persistent rods require culture and a documented plan rather than repeated empirical courses. Parasitic boundary: repeat the course after 10 days only for confirmed/suspected parasitic otitis under the label plan. Confirm Otodectes, examine/treat relevant in-contact animals and manage the environment; this repeat instruction is not for every bacterial or yeast episode. Tympanic/neurologic safety: stop and urgently reassess hearing loss, head tilt, nystagmus, ataxia, facial/Horner signs, severe pain or neurologic deterioration. Perforation is contraindicated and suspected middle-ear disease needs sampling/imaging/appropriate non-ototoxic care. Carbaryl safety: wear impermeable gloves and avoid skin/eye contact. Review organophosphates and other cholinesterase inhibitors; hypersalivation, vomiting/diarrhoea, miosis, fasciculation, weakness, dyspnoea or seizure may indicate systemic cholinergic toxicity. Feline contact-reaction warning: cats may deteriorate from topical contact dermatitis. Stop if erythema, suppuration, pruritus or pain worsens despite improving cytology; investigate polyp/mass and middle-ear disease rather than layering additional products. Reproduction and handling boundary: the exact label permits pregnancy and lactation at the recommended regimen, but modern quantified exact-product safety data are limited. Prevent licking/eye exposure, wash hands after use, keep the bottle from children and dispose as veterinary waste. Assessment sources +
Close
Composition / strength
Rifaximin 10 mg/ml Colistin 200000 IU/ml Miconazole 17.4 mg/ml Carbaryl 10 mg/ml Triamcinolone 0.908 mg/ml
Administration route
Into the ear
Manufacturer (register)
FATRO S.p.A. Ltd, Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 36, 19 Oct 2026.
Registration
Georgia
Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტოპეტ თერაპი
№ 1-03/44
Verified on: 23 Oct 2026
EU
Yes, veterinary
№ V/NRP/02/1490; 96/019/00-C; 96/151/99-S
Verified on: 23 Oct 2026
UK
No
US
No
Controlled in Georgia
Unknown
Information not fully verified
Complete labelled scope: dog/cat otitis externa associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation. Shake, clean carefully, instil 1-2 ml per affected external canal and massage twice daily for 7-10 days; repeat after 10 days only for parasitic otitis. This is a fixed per-ear volume, not a body-weight dose. Cytology and otoscopy determine whether the five-active combination is appropriate; recheck to documented resolution.
Cat
Weight Otitis externa · Into the ear
Any weight
1–2 ml
Otitis externa · Into the ear (twice daily for 7-10 days; for parasitic otitis repeat the course after 10 days): Shake well. Clean the ear carefully, instil 1-2 ml into the ear canal and massage to distribute over the external canal. Diagnose the primary cause; base antimicrobial use on organism identification and susceptibility testing where possible. Examine the external canal and tympanic membrane before treatment. Do not use with tympanic-membrane perforation, hypersensitivity or known ototoxic substances. Carbaryl can be absorbed through skin: handlers should wear gloves and avoid skin/eye contact. The Italian label reports no contraindication during pregnancy or lactation.
Source:
EU SPC 2023
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
OTOPET THERAPY ear drops for dogs and cats - Official Product Information
EU Veterinary Medicines Information, 2023
Dog
Weight Otitis externa · Into the ear
Any weight
1–2 ml
Otitis externa · Into the ear (twice daily for 7-10 days; for parasitic otitis repeat the course after 10 days): Shake well. Clean the ear carefully, instil 1-2 ml into the ear canal and massage to distribute over the external canal. Diagnose the primary cause; base antimicrobial use on organism identification and susceptibility testing where possible. Examine the external canal and tympanic membrane before treatment. Do not use with tympanic-membrane perforation, hypersensitivity or known ototoxic substances. Carbaryl can be absorbed through skin: handlers should wear gloves and avoid skin/eye contact. The Italian label reports no contraindication during pregnancy or lactation.
Source:
EU SPC 2023
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
OTOPET THERAPY ear drops for dogs and cats - Official Product Information
EU Veterinary Medicines Information, 2023
